Compromised calcium and phosphorus metabolism in patients with diabetes mellitus and chronic kidney disease
https://doi.org/10.14341/2072-0351-5542
Abstract
Disturbance of bone and mineral metabolism (BMM) is one of manifestations of chronic kidney disease (CKD), but its significance goes beyond bone disorders per se. Current discourse is as broad as to include vascular calcification, anemia and arterial hypertension, - conditions increasing mortality in patients with CKD. In this regard the active search for and development of novel approach to correction of BMM is under way. Apart from capacity to normalize calcium and phosphorus metabolism, parathyroid hormone secretion and to reduce morphologic alterations of bone tissue, modern therapeutic agents feature cardio- and renoprotective capabilities, which make them a treatment of choice for compromised BMM in CKD.
About the Authors
Margarita Stanislavovna Biragova
Endocrinology Research Centre
Russian Federation
Russian Federation
Svetlana Alexandrovna Gracheva
Endocrinology Research Centre
Russian Federation
Russian Federation
Sergey Andreevich Martynov
Endocrinology Research Centre
Russian Federation
Russian Federation
References
1. Maslova OV, Suntsov YI. Epidemiology of diabetes mellitus and microvascular complications. Diabetes mellitus. 2011;(3):6-11.
2. Shestakova MV, Dedov II. Sakharnyy diabet i khronicheskaya bolezn' pochek. Moscow: MIA; 2009. P.39.
3. Allen KV. Microalbuminuria and mortality in long-duration type 1 diabetes. Diabetes Care 2003; 26 (8): 2389-2391.
4. The International Diabetes Federation diabetes atlas methodology for estimating global and national prevalence of diabetes in adults. Diabetes Research and Clinical Practice. 2011 Dec; 94(3):322-332. doi:10.1016/j. diabres.2011.10.040
5. Henry RM, Kostense PJ, Bos G, Dekker JM, Nijpels G, Heine R.J, Bouter LM, Stehouwer CD. Mild renal insufficiency is associated with increased cardiovascular mortality: The Hoorn Study. Kidney Int. 2002 Oct;62(4):1402-1407.
6. Patel SS, Kimmel PL, Singh A. New clinical practice guidelines for chronic kidney disease: a framework for K/DOQI. Semin Nephrol. 2002 Nov;22(6):449-458.
7. Moe S. KDIGO is the registered mark of the kidney disease: Improving Global Outcomes. Kidney Int. 2006; 69:1945-1953.
8. Albright F, Reifenstein EC. Bone development in diabetic children: a roentgen study. Am J Med Sci. 1948; 174:313- 319.
9. Levin ME, Boisseau VC, Avoili LV. Effects of diabetes mellitus on bone mass in juvenile and adult-onset diabetes. N Engl J Med. 1976 Jan 29;294(5):241-245.
10. Brown SA, Sharpless J. Osteoporosis: an underappreciated complication of diabetes. Clin. Diabetes. 2004;(22):10 - 20. doi: 10.2337/diaclin.22.1.10
11. Belykh OA, Kochetkova OA. Sostoyanie kal'tsiy-fosfornogo obmena u bol'nykh sakharnym diabetom 1 tipa. Osteoporoz i osteopatii. 2005;(1):12-15.
12. Chechurin RE, Ametov AS. Sakharnyy diabet I tipa i osteoporoz (obzor literatury). Osteoporoz i osteopatii. 1999;(1): 2-5.
13. Nagasawa T. Bone histomorphometric osteopenia induced by ovarioectomy or diabetes mellitus in rat. Nihon Seikeigeka Gakkai Zasshi. 1995 Sep;69(9):699-707.
14. Santiago JV, McAlister WH, Ratzan SK, Bussman Y, Haymond MW, Shackelford G, Weldon VV. Decreased cortical thickness & osteopenia in children with diabetes mellitus. J Clin Endocrinol Metab. 1977 Oct;45(4):845-848.
15. Sugimoto T, Ritter C, Morrissey J, Hayes C, Slatopolsky E. Effects of high concentrations of glucose on PTH secretion in parathyroid cells. Kidney Int. 1990 Jun;37(6):1522-1527.
16. London GM, Marty C, Marchais SJ, Guerin AP, Metivier F, de Vernejoul MC. Arterial calcifications and bone histomorphometry in end-stage renal disease. J Am Soc Nephrol. 2004 Jul;15(7):1943-1951.
17. Stavroulopoulos A, Porter CJ, Pointon K, Monaghan JM, Roe SD, Cassidy M. Evolution of coronary artery calcification in patients with chronic kidney disease Stages 3 and 4, with and without diabetes. Nephrol Dial Transplant. 2011 Aug;26(8):2582-2589.
18. Milovanova LU, Nikolaev AYu, Milovanov US. Hyperphosphatemia as a cardiovascular risk factor in chronic renal failure (CRF) patients treated with haemodialysis. Nephrologia I dializ. 2002; 4(2):113-117.
19. Jono S, McKee MD, Murry CE, Shioi A, Nishizawa Y, Mori K, Morii H, Giachelli CM. Phosphate regulation of vascular smooth muscle cell calcification. Circ Res. 2000 Sep 29;87(7):E10-17.
20. Pletcher MJ, Tice JA, Pignone M, Browner WS. Using the Coronary Artery Calcium Score to Predict Coronary Heart Disease Events: A Systematic Review and Meta-analysis. Arch Intern Med. 2004 Jun 28;164(12):1285-1292.
21. Tuttle K, Short RA. Longitudinal relationships among coronary artery calcification, serum phosphorus, and kidney function. Clin J Am Soc Nephrol 2009; 4(12):1968-1973.
22. Cancela AL, Santos RD, Titan SM, Goldenstein PT, Rochitte CE, Lemos PA, Reis LM, Graciolli FG, Jorgetti V, MoysРs RРњ. Phosphorus Is Associated with Coronary Artery Disease in Patients with Preserved Renal Function. PLoS One. 2012;7(5):e36883.
23. Shimada T, Mizutani S, Muto T, Yoneya T, Hino R, Takeda S, Takeuchi Y, Fujita T, Fukumoto S, Yamashita T. Cloning end characterization of FGF 23 as a causative factor of tumor-induced osteomalacia. Proc Natl Acad Sci U S A. 2001 May 22;98(11):6500-6505.
24. Kurosu H, Ogawa Y, Miyoshi M, Yamamoto M, Nandi A, Rosenblatt KP, Baum MG, Schiavi S, Hu MC, Moe OW, Kuro-o M. Regulation of fibroblast growth factor-23 signaling by Klotho. J Biol Chem. 2006 Mar 10;281(10):6120-6123.
25. Naveh-Many T, Silver J. Regulation of parathyroid hormone gene expression by hypocalcemia, hypercalcemia, and vitamin D in the rat. J Clin Invest. 1990 Oct;86(4):1313- 1319.
26. Komaba H, Fukagawa M. FGF23: a key player in mineral and bone disorder in CKD. Nefrologia. 2009;29(5):392-396. DOI: 10.3265.
27. Ben-Dov IZ, Galitzer H, Lavi-Moshayoff V, Goetz R, Kuro-o M, Mohammadi M, Sirkis R, Naveh-Many T, Silver J. The parathyroid is a target organ for FGF23 in rats. J Clin Invest. 2007 Dec;117(12):4003-4008.
28. Titan SM, Zatz R, Graciolli FG, dos Reis LM, Barros RT, Jorgetti V, MoysГ©s RM. FGF-23 as a Predictor of Renal Outcome in Diabetic Nephropathy. Clin J Am Soc Nephrol. 2011 Feb;6(2):241-247.
29. Gutierrez OРњ, Mannstadt M, Isakova T, Rauh-Hain JA, Tamez H, Shah A, Smith K, Lee H, Thadhani R, Juppner H, Wolf M. Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N Engl J Med. 2008 Aug 7;359(6):584-592.
30. Jean G, Terrat JC, Vanel T, Hurot JM, Lorriaux C, Mayor B, Chazot C. High levels of serum fibroblast growth factor (FGF)-23 are associated with increased mortality in long haemodialysis patients. Nephrol Dial Transplant. 2009 Sep;24(9):2792-2796.
31. Parker BD, Schurgers LJ, Brandenburg VM, Christenson RH, Vermeer C, Ketteler M, Shlipak MG, Whooley MA, Ix JH. The associations of fibroblast growth factor 23 and uncarboxylated matrix Gla protein with mortality in coronary artery disease: Ann Intern Med. 2010 May 18;152(10):640- 648.
32. Gutierrez OM, Januzzi JL, Isakova T, Laliberte K, Smith K, Collerone G, Sarwar A, Hoffmann U, Coglianese E, Christenson R, Wang TJ, deFilippi C, Wolf M. Fibroblast growth factor 23 and left ventricular hypertrophy in chronic kidney disease. Circulation2009. 119(19): 2545-2552.
33. Mirza MA, Larsson A, Lind L, Larsson TE: Circulating fibroblast growth factor-23 is associated with vascular dysfunction in the community. Atherosclerosis. 2009. 205(2):385-390.
34. Mirza MA, Hansen T, Johansson L, AhlstrГm H, Larsson A, Lind L, Larsson TE. Relationship between circulating FGF23 and total body atherosclerosis in the community. Nephrol Dial Transplant. 2009 Oct;24(10):3125-3131.
35. Kuro-o M, Matsumura Y, Aizawa H, Kawaguchi H, Suga T, Utsugi T, Ohyama Y, Kurabayashi M, Kaname T, Kume E, Iwasaki H, Iida A, Shiraki-Iida T, Nishikawa S, Nagai R, Nabeshima YI. Mutation of the mouse klotho gene leads to a syndrome resembling ageing. Nature. 1997 Nov 6;390(6655):45-51.
36. Juppner HB. Parathyroid Hormone. Philadelphia: Lippincot, Williams & Wilkins; 1999.
37. Koch Nogueira PC, David L, Cochat P. Evolution of secondary hyperparathyroidism after renal transplantation. Pediatr Nephrol. 2000 Apr;14(4):342-346.
38. Nishimura M, Tsukamoto K, Tamaki N, Kikuchi K, Iwamot N, Ono T. Risk stratification for cardiac death in hemodialysis patients without obstructive coronary artery disease. Kidney Int. 2011 Feb;79(3):363-371.
39. Horl WH. The clinical consequences of secondary hyperparathyroidism: focus on clinical outcomes. Nephrol Dial Transplant. 2004 Aug;19 Suppl 5:V2-8.
40. Wang L, Jerosch-Herold M, Jacobs DR Jr, Shahar E, Detrano R, Folsom AR; MESA Study Investigators. Coronary Artery Calcification and Myocardial Perfusion in Asymptomatic Adults: The MESA (Multi-Ethnic Study of Atherosclerosis). J Am Coll Cardiol. 2006 Sep 5;48(5):1018-1026.
41. Goodman WG, Goldin J, Kuizon BD, Yoon C, Gales B, Sider D, Wang Y, Chung J, Emerick A, Greaser L, Elashoff RM, Salusky IB. Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med. 2000 May 18;342(20):1478-1483.
42. Simonet WS, Lacey DL, Dunstan CR, Kelley M, Chang MS, LГјthy R, Nguyen HQ, Wooden S, Bennett L, Boone T, Shimamoto G, DeRose M, Elliott R, Colombero A, Tan HL, Trail G, Sullivan J, Davy E, Bucay N, Renshaw-Gegg L, Hughes TM, Hill D, Pattison W, Campbell P, Sander S, Van G, Tarpley J, Derby P, Lee R, Boyle WJ. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell. 1997 Apr 18;89(2):309-319.
43. Luo G, Ducy P, McKee MD, Pinero GJ, Loyer E, Behringer RR, Karsenty G. Spontaneous calcification of arteries and cartilage in mice lacking matrix GLA protein. Nature. 1997 Mar 6;386(6620):78-81.
44. Schurgers LJ, Spronk HM, Soute BA, Schiffers PM, DeMey JG, Vermeer C. Regression of warfarin-induced medial elastocalcinosis by high intake of vitamin K in rats. Blood. 2007 Apr 1;109(7):2823-2831.
45. Frye MA, Melton LJ 3rd, Bryant SC, Fitzpatrick LA, Wahner HW, Schwartz RS, Riggs BL. Osteoporosis and calcification of the aorta. Bone Miner. 1992 Nov;19(2):185-194.
46. Rodríguez-García M, Gómez-Alonso C, Naves-Díaz M, Diaz-Lopez JB, Diaz-Corte C, Cannata-Andía JB; Asturias Study Group. Vascular calcifications, vertebral fractures and mortality in haemodialysis patients. Nephrol Dial Transplant. 2009 Jan;24(1):239-246.
47. Matias PJ, Ferreira C, Jorge C, Borges M, Aires I, Amaral T, Gil C, Cortez J, Ferreira A. 25-hydroxyvitamin D3, arterial calcifications and cardiovascular risk markers in haemodialysis patients. Nephrol Dial Transplant. 2009 Feb;24(2):611-618.
48. London GM, Marchais SJ, Guerin AP, Boutouyrie P, Metivier F, De Vernejoul MC. Association of bone activity, calcium load, aortic stiffness, and calcifications in ESRD. J Am Soc Nephrol. 2008 Sep;19(9):1827-1835.
49. National Kidney Foundation. K/DOQI Clinical Practice Guidelines for Bone Metabolism and Disease in Chronic Kidney Disease. Am J Kidney Dis. 2003 Oct;42(4 Suppl 3):S1-201.
50. Iimori S, Mori Y, Akita W, Takada S, Kuyama T, Ohnishi T, Shikuma S, Ishigami J, Tajima M, Asai T, Okado T, Kuwahara M, Sasaki S, Tsukamoto Y. Effects of sevelamer hydrochloride on mortality, lipid abnormality and arterial stiffness in hemodialyzed patients: a propensity-matched observational study. Clin Exp Nephrol. May 12 2012.
51. Di Iorio B, Bellasi A, Russo D. Mortality in kidney disease patients treated with phosphate binders: A Randomized Study. Clin J Am Soc Nephrol. 2012 Mar;7(3):487-493.
52. Kolbin AS, Proskurin MA, Kurylev AA, Balykina YuE. Kliniko-ekonomicheskiy analiz sevelamera pri khronicheskoy pochechnoy nedostatochnosti. Good clinical practice. 2012; (1):2-14.
53. Vlassara H, Uribarri J, Cai W, Goodman S, Pyzik R, Post J, Grosjean F, Woodward M, Striker GE. Effects of Sevelamer on HbA1c, inflammation, and advanced glycation end products in diabetic kidney disease. Clin J Am Soc Nephrol. 2012 Jun;7(6):934-942.
54. Zemchenkov AYu, Gerasimchuk RP. Vitamin D Receptor Activators and Vascular Calcification Review. Nefrologiya i dializ. 2009; 11(4): 276-292.
55. Hu J, Spiegel AM. Naturally occurring mutations of the extracellular Ca2+-sensing receptor: implications for its structure and function. Trends Endocrinol Metab. 2003 Aug;14(6):282-288.
56. Lindberg JS, Culleton B, Wong G, Borah MF, Clark RV, Shapiro WB, Roger SD, Husserl FE, Klassen PS, Guo MD, Albizem MB, Coburn JW. Cinacalcet HCl, an oral calcimimetic agent for the treatment of secondary hyperparathyroidism in hemodialysis and peritoneal dialysis: a randomized, doubleblind, multicenter study. J Am Soc Nephrol. 2005;16(3):800-807.
57. Wada M, Furuya Y, Sakiyama J, Kobayashi N, Miyata S, Ishii H, Nagano N. The calcimimetic compound NPS R-568 suppresses parathyroid cell proliferation in rats with renal insufficiency. Control of parathyroid cell growth via a calcium receptor. J Clin Invest. 1997 Dec 15;100(12):2977- 2983.
58. Wada M, Ishii H, Furuya Y, Fox J, Nemeth EF, Nagano N. NPS R-568 halts or reverses osteitis fibrosa in uremic rats. Kidney Int. 1998 Feb;53(2):448-453.
59. Tsuruta Y, Okano K, Kikuchi K, Tsuruta Y, Akiba T, Nitta K. Effects of cinacalcet on bone mineral density and bone markers in hemodialysis patients with secondary hyperparathyroidism. Clin Exp Nephrol. 2012 Jul 26.
60. The EVOLVE Trial Investigators: Effect of Cinacalcet on Cardiovascular Disease in Patients Undergoing Dialysis. N Engl J Med. 2012 Nov 3.
61. Raggi P, Chertow GM, Torres PU, Csiky B, Naso A, Nossuli K, Moustafa M, Goodman WG, Lopez N, Downey G, Dehmel B, Floege J; ADVANCE Study Group. The ADVANCE study: a randomized study to evaluate the effects of cinacalcet plus low-dose vitamin D on vascular calcification in patients on gemodialysis. Nephrol Dial Transplant. 2011 Apr;26(4):1327-1339.
62. Mpio I, Boumendjel N, Karaaslan H, Arkouche W, Lenz A, Cardozo C, Cardozo J, Pastural-Thaunat M, Fouque D, Silou J, Attaf D, Laville M. Secondary hyperparathyroidism and anemia. Effects of a calcimimetic on the control of anemia in chronic hemodialysed patients. Pilot Study. Nephrol Ther. 2011 Jul;7(4):229-236.
63. de Boer RA. Vitamin D and cardiovascular disease: a jack of all trades? J Renin Angiotensin Aldosterone Syst. 2011 Jun;12(2):123-124.
64. Li YC, Kong J, Wei M, Chen ZF, Liu SQ, Cao LP. 1,25-dihydroxyvitamin D3 is a negative endocrine regulator of the renin-angiotensin system. J Clin Invest. 2002 Jul;110(2):229-238.
65. Turner JM, Bauer C, Abramowitz MK, Melamed ML, Hostetter TH. Treatment of chronic kidney disease. Kidney Int. 2012 Feb;81(4):351-362.
66. de Zeeuw D, Agarwal R, Amdahl M, Audhya P, Coyne D, Garimella T, Parving HH, Pritchett Y, Remuzzi G, Ritz E, Andress D. Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): a randomised controlled trial. Lancet. 2010 Nov 6;376(9752):1543-1551.
67. Garfia B, Cañadillas S, Canalejo A, Luque F, Siendones E, Quesada M, Almadén Y, Aguilera-Tejero E, Rodríguez M. Regulation of parathyroid vitamin D receptor expression by extracellular calcium. J Am Soc Nephrol. 2002 Dec;13(12):2945-2952.
68. Drissi H, Pouliot A, Koolloos C, Stein JL, Lian JB, Stein GS, van Wijnen AJ. 1,25-(OH)2-vitamin D3 suppresses the bone-related Runx2. Cbfa1 gene promoter. Exp Cell Res. 2002 Apr 1;274(2):323-333.
69. Speer MY, McKee MD, Guldberg RE, Liaw L, Yang HY, Tung E, Karsenty G, Giachelli CM. Inactivation of the osteopontin gene enhances vascular calcification of matrix gla protein-deficient mice: evidence for osteopontin as an inducible inhibitor of vascular calcification in vivo. J Exp Med. 2002 Oct 21;196(8):1047-1055.
70. Joist HE, Ahya SN, Giles K, Norwood K, Slatopolsky E, Coyne DW. Differential effects of very high doses of doxercalciferol and paricalcitol on serum phosphorus in hemodialysis patients. Clin Nephrol. 2006 May;65(5):335- 341.
71. Sterz R, Frye РЎ, Khan S, et al. Paricalcitol treatment in CKD patients with secondary hyperparathyroidism associated with better health outcomes when compared with no vitamin D receptor (VDR) activator treatment. National Kidney Foundation. Spring Clinical Meeting Orlando, Florida, April 14-16, 2010. [Abstract]
72. Lau WL, Leaf EM, Hu MC, Takeno MM, Kuro-O M, Moe OW, Giachelli CM. Vitamin D receptor agonists increase klotho and osteopontin while decreasing aortic calcification in mice with chronic kidney disease fed a high phosphate diet. Kidney Int. 2012 Dec;82(12):1261-70. doi: 10.1038/ ki.2012.322.
73. Ari E, Kedrah AE, Alahdab Y, Bulut G, Eren Z, Baytekin O, Odabasi D. Antioxidant and renoprotective effects of paricalcitol on experimental contrast-induced nephropathy model. Br J Radiol. 2012 Aug;85(1016):1038-1043.
Review
For citations:
Biragova M.S., Gracheva S.A., Martynov S.A. Compromised calcium and phosphorus metabolism in patients with diabetes mellitus and chronic kidney disease. Diabetes mellitus. 2012;15(4):74-80. (In Russ.) https://doi.org/10.14341/2072-0351-5542
Views:
4453
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND 4.0).
Email this article 
